RT Journal Article
T1 Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
A1 Rocha-de-Lossada, Carlos
A1 Linero, Carmen Alba
A1 Ortega, Álvaro Santos
A1 Calvo-de-Mora, Marina Rodríguez
A1 Rachwani, Rahul
A1 Borroni, Davide
A1 Alba, Emilio
A1 Orgaz, Manuel Benavides
A1 Romano, Vito
AB The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
YR 2021
FD 2021-09-10
LK http://hdl.handle.net/10668/21667
UL http://hdl.handle.net/10668/21667
LA en
DS RISalud
RD Apr 8, 2025